STOCK TITAN

X4 Pharmaceuticals (XFOR) Stock News, May-Sep 2021

XFOR NASDAQ

X4 Pharmaceuticals, Inc. develops and commercializes therapies for rare hematology diseases, centered on mavorixafor, an oral CXCR4 antagonist marketed in the U.S. as XOLREMDI® in its first indication. Company news covers regulatory and commercial updates for XOLREMDI, including European authorization for WHIM syndrome and the Norgine license and supply relationship for selected ex-U.S. territories.

Recurring updates also address the 4WARD Phase 3 program evaluating mavorixafor in chronic neutropenia, quarterly financial results, product revenue, research and development spending, cash resources, restructuring effects, conference participation, and equity inducement grants under Nasdaq listing rules.

Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) is set to present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021, at 11:35 a.m. ET. Additionally, the company will participate in a fireside chat at the Cantor Global Healthcare Conference on September 30, 2021, at 10:00 a.m. ET. Live webcasts of both events will be accessible through the investors section of X4 Pharmaceuticals' website and will be archived for 90 days. X4 is focused on developing therapies for diseases linked to the CXCR4 pathway.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
conferences
-
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) promotes Mary DiBiase, Ph.D., to Chief Operating Officer, enhancing her responsibilities to include program management and IT oversight. DiBiase, with over 25 years in drug development, has been pivotal in advancing the company's lead candidate, mavorixafor, into late-stage clinical trials. CEO Paula Ragan emphasized her contributions to company growth and the potential commercialization of mavorixafor for treating diseases like WHIM syndrome. The company remains focused on developing innovative therapies targeting rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.00%
Tags
none
-
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) announced on August 31, 2021, that its Board's Compensation Committee issued an inducement award to new employees under its 2019 Inducement Equity Incentive Plan. The award consists of options to purchase a total of 20,350 shares of common stock at an exercise price of $5.13 per share, equal to the closing stock price on that date. The options have a ten-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter, contingent on continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
none
Rhea-AI Summary

BOSTON, Sept. 01, 2021 - X4 Pharmaceuticals (Nasdaq: XFOR) announced its participation in investor meetings at the Citi 16th Annual BioPharma Conference from September 8-10, 2021 and a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 AM ET. A live webcast of the fireside chat will be available on the company's investor section of their website for 90 days post-event. X4 specializes in therapies targeting diseases related to the CXCR4 pathway, with its lead candidate mavorixafor under evaluation in multiple clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences
-
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) will participate in a fireside chat at Canaccord Genuity’s 41st Annual Growth Conference on August 12, 2021, at 2:00 PM ET. The event will be accessible via a live webcast on the company's investor website, with an archive available for 90 days. X4 Pharmaceuticals focuses on developing therapies targeting the CXCR4 pathway, particularly for rare diseases. Their lead candidate, mavorixafor, is currently in various clinical trials, including a Phase 3 trial for WHIM syndrome.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.70%
Tags
conferences
-
Rhea-AI Summary

On August 3, 2021, X4 Pharmaceuticals (XFOR) announced key milestones in its clinical trials for mavorixafor. Enrollment in the pivotal Phase 3 trial for WHIM syndrome surpassed the minimum requirement, with top-line data expected in Q4 2022. The Phase 1b trial for Waldenström’s macroglobulinemia has also met its minimum enrollment, with results anticipated in Q4 2021. Financially, the company reported a net loss of $19.6 million for Q2 2021, up from $15.1 million in Q2 2020, indicating rising research and development costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) will report its financial results for Q2 ended June 30, 2021, on August 3, 2021. The company will also provide updates on recent business highlights during a conference call scheduled at 8:30 a.m. ET on the same day. Investors can access the call by dialing (866) 721-7655 or internationally at (409) 216-0009, using conference ID 2236266. X4 is developing mavorixafor, a novel therapy targeting the CXCR4 pathway, currently being evaluated in multiple clinical trials for rare diseases and cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
conferences earnings
-
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) announced the issuance of inducement awards to new employees under the 2019 Inducement Equity Incentive Plan on June 30, 2021. The awards include options to purchase a total of 10,850 shares at an exercise price of $6.50, equal to the closing price on that date. The options will vest over four years, with 25% vesting after one year. X4 is focused on developing therapies targeting the CXCR4 pathway, including its lead candidate mavorixafor, currently in multiple clinical trials for rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
none
-
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) announced promising preliminary efficacy and safety results from its Phase 1b clinical trial of mavorixafor combined with ibrutinib for Waldenström’s macroglobulinemia patients with MYD88 and CXCR4 mutations. Patients demonstrated robust serum IgM reductions of 60%-75%, exceeding previous monotherapy results of 38%-45%. Furthermore, all patients showed increases in hemoglobin levels, indicating reduced cancer burden. The trial continues with patient enrollment and dose escalation for further evaluation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.22%
Tags
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) announced a conference call and webcast to discuss initial efficacy and safety data from the Phase 1b trial of mavorixafor combined with ibrutinib in Waldenström’s Macroglobulinemia patients. This data will be presented during the European Hematology Association Annual Congress on June 11, 2021. The company aims to highlight the potential benefits of mavorixafor, a novel therapy targeting CXCR4 dysfunction, which is currently also evaluated in a Phase 3 trial for WHIM syndrome.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
conferences clinical trial

FAQ

What is the current stock price of X4 Pharmaceuticals (XFOR)?

X4 Pharmaceuticals (XFOR) last closed at $3.09.

What is the market cap of X4 Pharmaceuticals (XFOR)?

The market cap of X4 Pharmaceuticals (XFOR) is approximately $315.5M.